Antioxidant therapy as a potential approach to severe influenza-associated complications

Molecules

Volumn 16, Issue 3, 2011, Pages 2032-2052

  Uchide, Noboru ^a   Toyoda, Hiroo ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Antioxidant; Antiviral drug; Influenza

Indexed keywords

ANTIOXIDANT; ANTIVIRUS AGENT;

ARTICLE; HUMAN; INFLUENZA; INFLUENZA VIRUS A; ISOLATION AND PURIFICATION; VIROLOGY;

ANTIOXIDANTS; ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN;

EID: 79953068333     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16032032     Document Type: Article

References (97)

1. Peiris, J.S.; Tu, W.W.; Yen, H.L. A novel H1N1 virus causes the first pandemic of the 21st century. Eur. J. Immunol. 2009, 39, 2946-2954.
2. st century. J. Formos. Med. Assoc. 2009, 108, 526-532.
3. Rothberg, M.B.; Haessler, S.D. Complications of seasonal and pandemic influenza. Crit. Care Med. 2010, 38, e91-e97.
4. Girard, M.P.; Tam, J.S.; Assossou, O.M.; Kieny, M.P. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010, 28, 4895-4902.
5. World Health Organization. Pandemic (H1N1) 2009 - update 111. http://www.who.int/csr/don/2010-07-30/en/index.html (Accessed on 26 February 2011).
6. World Health Organization. Influenza updates. http://www.who.int/csr/don/ 2010-09-10/en/index.html (Accessed on 26 February 2011).
7. Kamps, B.S.; Reyes-Terán, G. Influenza. In Influenza Report; Kamps, B.S., Hoffmann, C., Preiser, W., Eds.; Flying Publishers: Paris, France, 2006; pp. 17-47.
8. Beigel, J.; Bray, M. Current and future antiviral therapy of severe seasonal and avian influenza. Antivir. Res. 2008, 78, 91-102.
9. Centers for Disease Control and Prevention (CDC). Update: Drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 433-435.
10. World Health Organization. Pandemic (H1N1) 2009 - update 60. http://www.who.int/csr/don/2009-08-04/en/index.html (Accessed on 26 February 2011).
11. World Health Organization. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly. Epidemiol. Rec. 2010, 85, 37-40.
12. Sugaya, N.; Ohashi, Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 2010, 54, 2575-2582.
13. Bearman, G.M.; Shankaran, S.; Elam, K. Treatment of severe cases of pandemic (H1N1) 2009 influenza: Review of antivirals and adjuvant therapy. Recent Patents Antiinfect. Drug Discov. 2010, 5, 152-156.
14. Nasu, T.; Ogawa, D.; Wada, J.; Makino, H. Peramivir for severe influenza infection in a patient with diabetic nephropathy. Am. J. Respir. Crit. Care Med. 2010, 182, 1209-1210.
15. Renaud, C.; Pergam, S.A.; Polyak, C.; Jain, R.; Kuypers, J.; Englund, J.A.; Corey, L.; Boeckh, M.J. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl. Infect. Dis. 2010, 12, 513-517.
16. Cunha, B.A.; Syed, U.; Mickail, N. Fulminant fatal swine influenza (H1N1): Myocarditis, myocardial infarction, or severe influenza pneumoniaγ Heart Lung 2010, 39, 453-458.
17. Nguyen, J.T.; Hoopes, J.D.; Le, M.H.; Smee, D.F.; Patick, A.K.; Faix, D.J.; Blair, P.J.; de Jong, M.D.; Prichard, M.N.; Went, G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5, e9332.
18. Tumpey, T.M.; García-Sastre, A.; Taubenberger, J.K.; Palese, P.; Swayne, D.E.; Pantin-Jackwood, M.J.; Schultz-Cherry, S.; Solórzano, A.; Van Rooijen, N.; Katz, J.M.; Basler, C.F. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: Functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 2005, 79, 14933-14944. (Pubitemid 41636290)
19. Uchide, N.; Toyoda, H. Current status of monocyte differentiation- inducing (MDI) factors derived from human fetal membrane chorion cells undergoing apoptosis after influenza virus infection. Gene Regul. Syst. Biol. 2007, 1, 295-302.
20. Akaike, T.; Suga, M.; Maeda, H. Free radicals in viral pathogenesis: Molecular mechanisms involving superoxide and NO. Proc. Soc. Exp. Biol. Med. 1998, 217, 64-73.
21. Uchide, N.; Toyoda, H. Potential of selected antioxidants for influenza chemotherapy. Anti-Infect. Agents Med. Chem. 2008, 7, 73-83. (Pubitemid 351761447)
22. Uchide, N.; Toyoda, H. Future target molecules for influenza treatment. Mini-Rev. Med. Chem. 2008, 8, 491-495.
23. Oda, T.; Akaike, T.; Hamamoto, T.; Suzuki, F.; Hirano, T.; Maeda, H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 1989, 244, 974-976. (Pubitemid 19152287)
24. Sidwell, R.W.; Huffman, J.H.; Bailey, K.W.; Wong, M.H.; Nimrod, A.; Panet, A. Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice. Antimicrob. Agents Chemother. 1996, 40, 2626-2631. (Pubitemid 26367656)
25. Serkedjieva, J.; Roeva, I.; Angelova, M.; Dolashka, P.; Voelter, W.G. Combined protective effect of a fungal Cu/Zn-containing superoxide dismutase and rimantadine hydrochloride in experimental murine influenza a virus infection. Acta Virol. 2003, 47, 53-56. (Pubitemid 36604531)
26. 2 - generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J. Clin. Invest. 1990, 85, 739-745. (Pubitemid 20087476)
27. Suliman, H.B.; Ryan, L.K.; Bishop, L.; Folz, R.J. Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 280, L69-L78.
28. Snelgrove, R.J.; Edwards, L.; Rae, A.J.; Hussell, T. An absence of reactive oxygen species improves the resolution of lung influenza infection. Eur. J. Immunol. 2006, 36, 1364-1373. (Pubitemid 43942127)
29. Shi, Y.; Niculescu, R.; Wang, D.; Patel, S.; Davenpeck, K.L.; Zalewski, A. Increased NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 739-745. (Pubitemid 32448762)
30. Uchide, N.; Ohyama, K. Antiviral function of pyrrolidine dithiocarbamate against influenza virus: The inhibition of viral gene replication and transcription. J. Antimicrob. Chemother. 2003, 52, 8-10. (Pubitemid 36850077)
31. Uchide, N.; Ohyama, K.; Bessho, T.; Yuan, B.; Yamakawa, T. Effect of antioxidants on apoptosis induced by influenza virus infection: Inhibition of viral gene replication and transcription with pyrrolidine dithiocarbamate. Antivir. Res. 2002, 56, 207-217. (Pubitemid 35284295)
32. Knobil, K.; Choi, A.M.; Weigand, G.W.; Jacoby, D.B. Role of oxidants in influenza virus-induced gene expression. Am. J. Physiol. 1998, 274, L134-L142.
33. Lowy, R.J.; Dimitrov, D.S. Characterization of influenza virus-induced death of J774.1 macrophages. Exp. Cell Res. 1997, 234, 249-258. (Pubitemid 27335165)
34. McKinney, L.C.; Galliger, S.J.; Lowy, R.J. Active and inactive influenza virus induction of tumor necrosis factor-a and nitric oxide in J774.1 murine macrophages: Modulation by interferon-γ and failure to induce apoptosis. Virus Res. 2003, 97, 117-126. (Pubitemid 37352934)
35. Chen, K.; Long, Y.M.; Wang, H.; Lan, L.; Lin, Z.H. Activation of nuclear factor-kB and effects of pyrrolidine dithiocarbamate on TNBS-induced rat colitis. World J. Gastroenterol. 2005, 11, 1508-1514. (Pubitemid 40468087)
36. Cuzzocrea, S.; Chatterjee, P.K.; Mazzon, E.; Dugo, L.; Serraino, I.; Britti, D.; Mazzullo, G.; Caputi, A.P.; Thiemermann, C. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br. J. Pharmacol. 2002, 135, 496-510. (Pubitemid 34151183)
37. Mallick, I.H.; Yang, W.X.; Winslet, M.C.; Seifalian, A.M. Pyrrolidine dithiocarbamate reduces ischemia-reperfusion injury of the small intestine. World J. Gastroenterol. 2005, 11, 7308-7313. (Pubitemid 43137681)
38. Yang, C.H.; Fang, I.M.; Lin, C.P.; Yang, C.M.; Chen, M.S. Effects of the NF-kB inhibitor pyrrolidine dithiocarbamate on experimentally induced autoimmune anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2005, 46, 1339-1347.
39. Kim, C.H.; Kim, J.H.; Hsu, C.Y.; Ahn, Y.S. Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-kB activation. FEBS Lett. 1999, 449, 28-32. (Pubitemid 29182664)
40. Oxford, J.S.; Perrin, D.D. Inhibition of the particle-associated RNA-dependent RNA polymerase activity of influenza viruses by chelating agents. J. Gen. Virol. 1974, 23, 59-71.
41. Si, X.; McManus, B.M.; Zhang, J.; Yuan, J.; Cheung, C.; Esfandiarei, M.; Suarez, A.; Morgan, A.; Luo, H. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J. Virol. 2005, 79, 8014-8023. (Pubitemid 40853505)
42. Krenn, B.M.; Holzer, B.; Gaudernak, E.; Triendl, A.; van Kuppeveld, F.J.; Seipelt, J. Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions. J. Virol. 2005, 79, 13892-13899. (Pubitemid 41552688)
43. Uchide, N.; Ohyama, K.; Bessho, T.; Toyoda, H. Effects of mitogen-activated protein kinase inhibitors on tumor necrosis factor-a gene expression and apoptosis induction in cultured human fetal membrane chorion cells infected with influenza virus. Intervirology 2007, 50, 99-107.
44. Chiou, W.F.; Chen, C.C.; Wei, B.L. 8-Prenylkaempferol suppresses influenza A virus-induced RANTES production in A549 cells via blocking PI3K-mediated transcriptional activation of NF-kB and IRF3. Evid. Based Complement. Altern. Med. 2009, In Press.
45. Kelly, G.S. Clinical applications of N-acetylcysteine. Altern. Med. Rev. 1998, 3, 114-127. (Pubitemid 128709607)
46. Saito, T.; Tanaka, M.; Yamaguchi, I. Effect of brefeldin A on influenza A virus-induced apoptosis in vitro. J. Vet. Med. Sci. 1996, 58, 1137-1139. (Pubitemid 126478423)
47. Lin, C.; Zimmer, S.G.; Lu, Z.; Holland, R.E., Jr.; Dong, Q.; Chambers, T.M. The involvement of a stress-activated pathway in equine influenza virus-mediated apoptosis. Virology 2001, 287, 202-213. (Pubitemid 32778252)
48. Geiler, J.; Michaelis, M.; Naczk, P.; Leutz, A.; Langer, K.; Doerr, H.W.; Cinatl, J., Jr. N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem. Pharmacol. 2009, 79, 413-420.
49. Ungheri, D.; Pisani, C.; Sanson, G.; Bertani, A.; Schioppacassi, G.; Delgado, R.; Sironi, M.; Ghezzi, P. Protective effect of N-acetylcysteine in a model of influenza infection in mice. Int. J. Immunopathol. Pharmacol. 2000, 13, 123-128. (Pubitemid 32001492)
50. Ghezzi, P.; Ungheri, D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int. J. Immunopathol. Pharmacol. 2004, 17, 99-102. (Pubitemid 39572194)
51. Garozzo, A.; Tempera, G.; Ungheri, D.; Timpanaro, R.; Castro, A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int. J. Immunopathol. Pharmacol. 2007, 20, 349-354. (Pubitemid 47104855)
52. De Flora, S.; Grassi, C.; Carati, L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur. Respir. J. 1997, 10, 1535-1541. (Pubitemid 27311068)
53. Lai, K.Y.; Ng, W.Y.; Osburga Chan P.K.; Wong, K.F.; Cheng, F. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann. Intern. Med. 2010, 152, 687-688.
54. Cai, J.; Chen, Y.; Seth, S.; Furukawa, S.; Compans, R.W.; Jones, D.P. Inhibition of influenza infection by glutathione. Free Radic. Biol. Med. 2003, 34, 928-936. (Pubitemid 36316077)
55. Nencioni, L.; Iuvara, A.; Aquilano, K.; Ciriolo, M.R.; Cozzolino, F.; Rotilio, G.; Garaci, E.; Palamara, A.T. Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2. FASEB J. 2003, 17, 758-760.
56. Floriano-Sanchez, E.; Villanueva, C.; Medina-Campos, O.N.; Rocha, D.; Sanchez-Gonzalez, D.J.; Cardenas-Rodriguez, N.; Pedraza-Chaverri, J. Nordihydroguaiaretic acid is a potent in vitro scavenger of peroxynitrite, singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid and prevents in vivo ozone-induced tyrosine nitration in lungs. Free Radic. Res. 2006, 40, 523-533.
57. Lü, J.M.; Nurko, J.; Weakley, S.M.; Jiang, J.; Kougias, P.; Lin, P.H.; Yao, Q.; Chen, C. Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: An update. Med. Sci. Monit. 2010, 16, RA93-RA100.
58. Uchide, N.; Ohyama, K.; Bessho, T.; Toyoda, H. Inhibition of influenza virus-induced apoptosis in chorion cells of human fetal membranes by nordihydroguaiaretic acid. Intervirology 2005, 48, 336-340. (Pubitemid 40868968)
59. Chen, Q.; Andrea, B.J. Scalable synthetic process for making terameprocol. WO/2010/014936, 4 February 2010.
60. Eads, D.; Hansen, R.; Oyegunwa, A.; Cecil, C.; Culver, C.; Scholle, F.; Petty, I.; Laster, S. Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokines. J. Inflamm. (Lond.) 2009, 6, 2.
61. Craigo, J.; Callahan, M.; Huang, R.C.; DeLucia, A.L. Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives. Antivir. Res. 2000, 47, 19-28. (Pubitemid 30621393)
62. Tagaya, M.; Henomatsu, N.; Yoshimori, T.; Yamamoto, A.; Tashiro, Y.; Mizushima, S. Inhibition of vesicle-mediated protein transport by nordihydroguaiaretic acid. J. Biochem. 1996, 119, 863-869. (Pubitemid 26182367)
63. Nozoe, T. Uber die farbstoffe im holzteile des "Hinoki" baumes. I. hinokitin und hinokitiol. Bull. Chem. Soc. Jpn. 1936, 11, 295-298.
64. Miyamoto, D.; Kusagaya, Y.; Endo, N.; Sometani, A.; Takeo, S.; Suzuki, T.; Arima, Y.; Nakajima, K.; Suzuki, Y. Thujaplicin-copper chelates inhibit replication of human influenza viruses. Antivir. Res. 1998, 39, 89-100. (Pubitemid 29027860)
65. Arima, Y.; Hatanaka, A.; Tsukihara, S.; Fujimoto, K.; Fukuda, K.; Sakurai, H. Scavenging activities of α-, β- and γ-thujaplicins against active oxygen species. Chem. Pharm. Bull. 1997, 45, 1881-1886 (Pubitemid 28047293)
66. Martinez, J.; Moreno, J.J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 2000, 59, 865-870. (Pubitemid 30081710)
67. Palamara, A.T.; Nencioni, L.; Aquilano, K.; De Chiara, G.; Hernandez, L.; Cozzolino, F.; Ciriolo, M.R.; Garaci, E. Inhibition of influenza A virus replication by resveratrol. J. Infect. Dis. 2005, 191, 1719-1729. (Pubitemid 40656761)
68. Huang, Y.L.; Loke, S.H.; Hsu, C.C.; Chiou, W.F. (+)-Vitisin A inhibits influenza A virus-induced RANTES production in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation. Planta Med. 2008, 74, 156-162.
69. Huang, Y.L.; Tsai, W.J.; Shen, C.C.; Chen, C.C. Resveratrol derivatives from the roots of Vitis thunbergii. J. Nat. Prod. 2005, 68, 217-220.
70. García-Alonso, M.; Rimbach, G.; Rivas-Gonzalo, J.C.; De Pascual-Teresa, S. Antioxidant and cellular activities of anthocyanins and their corresponding vitisins A - studies in platelets, monocytes, and human endothelial cells. J. Agric. Food Chem. 2004, 52, 3378-3384.
71. Huang, K.S.; Lin, M.; Cheng, G.F. Anti-inflammatory tetramers of resveratrol from the roots of Vitis amurensis and the conformations of the seven-membered ring in some oligostilbenes. Phytochemistry 2001, 58, 357-362. (Pubitemid 32847320)
72. Huang, Y.L.; Loke, S.H.; Hsu, C.C.; Chiou, W.F. (+)-Vitisin A inhibits influenza A virus-induced RANTES production in A549 alveolar epithelial cells through interference with Akt and STAT1 phosphorylation. Planta Med. 2008, 74, 156-162.
73. Germouty, J.; Jirou-Najou, J.L. Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses. Respiration 1987, 51, 37-41. (Pubitemid 17070800)
74. Yang, B.; Yao, D.F.; Ohuchi, M.; Ide, M.; Yano, M.; Okumura, Y.; Kido, H. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002, 19, 952-958. (Pubitemid 34567912)
75. Gillissen, A.; Bartling, A.; Schoen, S.; Schultze-Werninghaus, G. Antioxidant function of ambroxol in mononuclear and polymorphonuclear cells in vitro. Lung 1997, 175, 235-242. (Pubitemid 27260312)
76. Gillissen, A.; Schärling, B.; Jaworska, M.; Bartling, A.; Rasche, K.; Schultze-Werninghaus, G. Oxidant scavenger function of ambroxol in vitro: A comparison with N-acetylcysteine. Res. Exp. Med. (Berl.) 1997, 196, 389-398. (Pubitemid 27129352)
77. Nobata, K.; Fujimura, M.; Ishiura, Y.; Myou, S.; Nakao, S. Ambroxol for the prevention of acute upper respiratory disease. Clin. Exp. Med. 2006, 6, 79-83.
78. Tsujimoto, Y.; Hashizume, H.; Yamazaki, M. Superoxide radical scavenging activity of phenolic compounds. Int. J. Biochem. 1993, 25, 491-494. (Pubitemid 23094438)
79. Jariwalla, R.J.; Roomi, M.W.; Gangapurkar, B.; Kalinovsky, T.; Niedzwiecki, A.; Rath, M. Suppression of influenza A virus nuclear antigen production and neuraminidase activity by a nutrient mixture containing ascorbic acid, green tea extract and amino acids. Biofactors 2007, 31, 1-15. (Pubitemid 352032101)
80. Furuya, A.; Uozaki, M.; Yamasaki, H.; Arakawa, T.; Arita, M.; Koyama, A.H. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. Int. J. Mol. Med. 2008, 22, 541-545.
81. Kimbarowski, J.A.; Mokrow, N.J. Colored precipitation reaction of the urine according to Kimbarowski (FARK) as an index of the effect of ascorbic acid during treatment of viral influenza. Dtsch. Gesundheitsw. 1967, 22, 2413-2418.
82. Banerjee, D.; Kaul, D. Combined inhalational and oral supplementation of ascorbic acid may prevent influenza pandemic emergency: A hypothesis. Nutrition 2010, 26, 128-132.
83. Robak, J.; Gryglewski, R.J. Bioactivity of flavonoids. Pol. J. Pharmacol. 1996, 48, 555-564. (Pubitemid 27127999)
84. Nagai, T.; Miyaichi, Y.; Tomimori, T.; Yamada, H. Inhibition of mouse liver sialidase by plant flavonoids. Biochem. Biophys. Res. Commun. 1989, 163, 25-31. (Pubitemid 19227264)
85. Nagai, T.; Miyaichi, Y.; Tomimori, T.; Suzuki, Y.; Yamada, H. Inhibition of influenza virus sialidase and anti-influenza virus activity by plant flavonoids. Chem. Pharm. Bull. (Tokyo) 1990, 38, 1329-1332. (Pubitemid 20290829)
86. Nagai, T.; Miyaichi, Y.; Tomimori, T.; Suzuki, Y.; Yamada, H. In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase. Antivir. Res. 1992, 19, 207-217.
87. Nagai, T.; Suzuki, Y.; Tomimori, T.; Yamada, H. Antiviral activity of plant flavonoid, 5,7,4'-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis against influenza A (H3N2) and B viruses. Biol. Pharm. Bull. 1995, 18, 295-299.
88. Nagai, T.; Moriguchi, R.; Suzuki, Y.; Tomimori, T.; Yamada, H. Mode of action of the anti-influenza virus activity of plant flavonoid, 5,7,4'-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis. Antivir. Res. 1995, 26, 11-25.
89. Song, J.M.; Lee, K.H.; Seong, B.L. Antiviral effect of catechins in green tea on influenza virus. Antivir. Res. 2005, 68, 66-74.
90. Kashima, M. Effects of catechins on superoxide and hydroxyl radical. Chem. Pharm. Bull. (Tokyo) 1999, 47, 279-283. (Pubitemid 29114070)
91. Yamada, H.; Takuma, N.; Daimon, T.; Hara, Y. Gargling with tea catechin extracts for the prevention of influenza infection in elderly nursing home residents: A prospective clinical study. J. Altern. Complement. Med. 2006, 12, 669-672. (Pubitemid 46141019)
92. Mori, S.; Miyake, S.; Kobe, T.; Nakaya, T.; Fuller, S.D.; Kato, N.; Kaihatsu, K. Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3- O-gallate fatty acid monoester derivatives: Effect of alkyl chain length. Bioorg. Med. Chem. Lett. 2008, 18, 4249-4952.
93. Kuzuhara, T.; Iwai, Y.; Takahashi, H.; Hatakeyama, D.; Echigo, N. Green tea catechins inhibit the endonuclease activity of influenza A virus RNA polymerase. PLoS. Curr. 2009, 1, RRN1052.
94. Choi, H.J.; Song, J.H.; Park, K.S.; Kwon, D.H. Inhibitory effects of quercetin 3-rhamnoside on influenza A virus replication. Eur. J. Pharm. Sci. 2009, 37, 329-333.
95. Kim, Y.; Narayanan, S.; Chang, K.O. Inhibition of influenza virus replication by plant-derived isoquercetin. Antivir. Res. 2010, 88, 227-235.
96. Fujii, H.; Sun, B.; Nishioka, H.; Hirose, A.; Aruoma, O.I. Evaluation of the safety and toxicity of the oligomerized polyphenol Oligonol. Food Chem. Toxicol. 2007, 45, 378-387. (Pubitemid 46176361)
97. Gangehei, L.; Ali, M.; Zhang, W.; Chen, Z.; Wakame, K.; Haidari, M. Oligonol a low molecular weight polyphenol of lychee fruit extract inhibits proliferation of influenza virus by blocking reactive oxygen species-dependent ERK phosphorylation. Phytomedicine 2010, 17, 1047-1056.